drugset
drugset / Trial / NCT02180711

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

NCT02180711 ↗

Phase 1/2 Active not recruiting 113 enrolled Acerta Pharma BV AstraZeneca · collab
NaParallel-groupOpen-labelTreatment

Summary

Part 1: To characterize the safety profile of acalabrutinib alone or in combination with rituximab in subjects with R/R FL. Part 2: To characterize the activity of acalabrutinib alone or in combination with rituximab in subjects with R/R MZL, as measured by ORR. Part 3: To characterize the safety of acalabrutinib in combination with rituximab and lenalidomide in subjects with R/R FL

Timeline

Start
2014-12-29
Primary completion
2023-08-25
Completion
2028-12-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule — —
Subject Lenalidomide Other / unclassified — —
Subject Rituximab Monoclonal antibody — Intravenous

Indications

B-cell non-Hodgkin lymphoma